The Asia Pacific nasal spray devices market is expected to proliferate at a CAGR of 7.37% during the forecasting years of 2019-2027. Asia-Pacific nasal spray devices market will be on up-surging trend primarily due to the increase in the prevalence of asthma.
China, India, Japan, Australia, South Korea and the collective nations under the Rest of Asia Pacific regional segment are the major countries considered for market analysis. The India market for nasal spray devices is advancing at a significant pace due to the increasing cases of allergic rhinitis, chronic obstructive pulmonary disease (COPD) and growing air pollution level in the country.
The nasal spray devices market is segmented on the basis of product, prescription, therapeutic, application, and end-user. The various incidences of product recall reported recently by FDA or companies itself act as a restraining factor for global nasal spray devices market over the forecast period.
GlaxoSmithKline, Sun Pharmaceuticals Industries, Ltd., Sanofi-Aventis S.A., Becton Dickinson and Company, Sandoz International GmbH (subsidiary of Novartis AG), Apotex, Mylan NV, Pfizer, Inc., Adapt Pharma, Inc. (acquired by Emergent BioSolutions), Allergan Inc., Hikma Pharmaceuticals PLC, Beximco Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Cipla are some of the major companies operating in the market that are mentioned in the report.